Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Equity Income (2021 - 2023)

ImmunityBio (IBRX) has disclosed Equity Income for 3 consecutive years, with -$1.3 million as the latest value for Q3 2023.

  • On a quarterly basis, Equity Income rose 71.84% to -$1.3 million in Q3 2023 year-over-year; TTM through Jun 2024 was -$1.3 million, a 91.23% increase, with the full-year FY2023 number at -$7.5 million, up 37.65% from a year prior.
  • Equity Income was -$1.3 million for Q3 2023 at ImmunityBio, up from -$4.0 million in the prior quarter.
  • In the past five years, Equity Income ranged from a high of -$197000.0 in Q1 2022 to a low of -$4.5 million in Q3 2022.
  • A 3-year average of -$2.6 million and a median of -$2.9 million in 2022 define the central range for Equity Income.
  • Biggest YoY gain for Equity Income was 71.84% in 2023; the steepest drop was 1086.29% in 2023.
  • ImmunityBio's Equity Income stood at -$803000.0 in 2021, then plummeted by 342.59% to -$3.6 million in 2022, then skyrocketed by 64.69% to -$1.3 million in 2023.
  • Per Business Quant, the three most recent readings for IBRX's Equity Income are -$1.3 million (Q3 2023), -$4.0 million (Q2 2023), and -$2.3 million (Q1 2023).